Life science company Epitopea, rooted in Cambridge UK and both Montreal and Quebec in Canada, has clinched a licensing deal ...

The European Commission (EC) has conditionally approved MSD's Welireg, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, as a single agent for the treatment of adults with von Hippel-Lindau ...

South Korean pharmaceutical company Hanmi Pharmaceutical has reported positive outcomes from a Phase I/II clinical trial of ...

This is a 20% increase from the previous year. It indicates that investments in the pharmaceutical sector are increasingly concentrated in China. U.S. company Merck (MSD) signed an exclusive license ...

Hanmi Pharmaceutical confirms positive results for Tibumeshirnon and Keytruda in cancer trial Phase 2 trial highlights ...

MSD Ireland's robust R&D pipeline of therapeutic projects ensures it is ready to meet the diverse needs of patients globally ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

PAC Machinery will demonstrate how its Rollbag R785 Automatic Bagger integrated with robotics enhances packaging efficiency ...

Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), a late-stage biotechnology developing impactful treatments for neuropsychiatric ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

PHRMAG represents 29 leading global biopharmaceutical research companies in the region. Dedicated to advancing innovation and ...

Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...